Get Help, or Donate to a Family in Need

The Tom Coughlin Jay Fund Foundation was created in 1996 in the honor of Jay McGillis. Jay was a very special young man who developed leukemia while a member of the football team at Boston College. Tom Coughlin was inspired by the courage, compassion and faith he and his family demonstrated during the course of his illness. Coughlin witnessed first hand the financial and emotional struggles the family suffered through and vowed to help people in the same situation if he ever had the opportunity.

The mission of the Tom Coughlin Jay Fund Foundation is to assist children with leukemia and other cancers and their families by providing emotional and financial support to help reduce the stress associated with treatment and improve their quality of life. Many times a parent must miss work to be with a child who is hospitalized or requires home care. The decreased income combined with the medical expenses creates a tremendous financial burden. The Jay Fund attempts to alleviate some of this burden so a family can focus on the health of their child.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap